fenylefrin abcur 0.05 mg/ ml
abcur ab - fenylefrinhydroklorid - injeksjonsvæske, oppløsning - 0.05 mg/ ml
palladon 4 mg
mundipharma as - hydromorfonhydroklorid - depotkapsel, hard - 4 mg
hydromorfonhydroklorid kalceks 10 mg/ ml
as kalceks - hydromorfonhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 10 mg/ ml
hydromorfonhydroklorid kalceks 20 mg/ ml
as kalceks - hydromorfonhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 20 mg/ ml
hydromorfonhydroklorid kalceks 50 mg/ ml
as kalceks - hydromorfonhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 50 mg/ ml
amiodaron hameln 50 mg/ ml
hameln pharma gmbh - amiodaronhydroklorid - konsentrat til injeksjons-/infusjonsvæske, oppløsning - 50 mg/ ml
hydromorfonhydroklorid kalceks 2 mg/ ml
as kalceks - hydromorfonhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml
dexdor
orion corporation - dexmedetomidine hydrochloride - bevisst sedasjon - psykoleptiske - for sedasjon av voksne intensivavhengige pasienter som krever et sederingsnivå ikke dypere enn oppsving som følge av verbal stimulering (tilsvarende richmond agitation-sedation scale (rass) 0 til -3).
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.